Correlation Between Boston Scientific and UroGen Pharma

Can any of the company-specific risk be diversified away by investing in both Boston Scientific and UroGen Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Boston Scientific and UroGen Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Boston Scientific Corp and UroGen Pharma, you can compare the effects of market volatilities on Boston Scientific and UroGen Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Boston Scientific with a short position of UroGen Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Boston Scientific and UroGen Pharma.

Diversification Opportunities for Boston Scientific and UroGen Pharma

-0.07

Correlation Coefficient

Boston Scientific  UroGen Pharma

Good diversification

The 3 months correlation between Boston and UroGen is -0.07. Overlapping area represents the amount of risk that can be diversified away by holding Boston Scientific Corp and UroGen Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on UroGen Pharma and Boston Scientific is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Boston Scientific Corp are associated (or correlated) with UroGen Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of UroGen Pharma has no effect on the direction of Boston Scientific i.e., Boston Scientific and UroGen Pharma go up and down completely randomly.

Pair Corralation between Boston Scientific and UroGen Pharma

Considering the 90-day investment horizon Boston Scientific Corp is expected to generate 0.5 times more return on investment than UroGen Pharma. However, Boston Scientific Corp is 1.98 times less risky than UroGen Pharma. It trades about 0.14 of its potential returns per unit of risk. UroGen Pharma is currently generating about 0.06 per unit of risk. If you would invest  8,968  in Boston Scientific Corp on December 28, 2024 and sell it today you would earn a total of  1,112  from holding Boston Scientific Corp or generate 12.4% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Boston Scientific Corp  vs.  UroGen Pharma

Boston Scientific Corp

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Boston Scientific Corp are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of fairly conflicting basic indicators, Boston Scientific showed solid returns over the last few months and may actually be approaching a breakup point.

UroGen Pharma

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in UroGen Pharma are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating technical and fundamental indicators, UroGen Pharma may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Pair Trading with Boston Scientific and UroGen Pharma

The main advantage of trading using opposite Boston Scientific and UroGen Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Boston Scientific position performs unexpectedly, UroGen Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in UroGen Pharma will offset losses from the drop in UroGen Pharma's long position.

The idea behind Boston Scientific Corp and UroGen Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.